EQUITY RESEARCH MEMO

Laborie

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)55/100

Laborie is a private medical technology company with a 60-year legacy in developing diagnostic and therapeutic solutions for urology, gastroenterology, and obstetrics/gynecology/neonatal care. Headquartered in Portsmouth, NH, the company focuses on patient-centered technologies that support entire care pathways. Its product portfolio includes urodynamic systems, pelvic floor diagnostics, anorectal manometry, and neonatal care devices, with recurring revenue from consumables and capital equipment. As a private firm, financial details are not publicly available, but the company is well-established in niche markets with steady demand. Growth prospects likely stem from expanding its product line, geographic expansion, and strategic partnerships. However, competition from larger medtech players and regulatory risks remain challenges. Overall, Laborie represents a stable but low-visibility opportunity in the diagnostics sector.

Upcoming Catalysts (preview)

  • Q4 2026Launch of AI-Enhanced Urodynamics System65% success
  • Q3 2026FDA 510(k) Clearance for New Anorectal Manometry Device50% success
  • Q2 2026Strategic Partnership with Large Hospital Network for Distribution70% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)